Keyword: CRISPR Therapeutics
CRISPR is a promising treatment for blood disorders, but it comes with challenges, such as off-target effects.
Longtime Catalent CFO joins Allergan, Arcturus board and ousted CEO exchange fire, Lilly diabetes executive jumps to MannKind.
News of Lundberg’s departure emerged on the same day Celgene revealed it has sold another chunk of its once-double-digit stake in the startup.
A new journal paper has found that the CRISPR-Cas9 gene-editing technique could be under threat from the body’s own immune system.
Intellia Therapeutics has named John Leonard, M.D., as its new president and chief as former leader and founder Nessan Bermingham, Ph.D., departs.
Vertex and CRISPR will co-develop a beta-thalassemia and sickle cell treatment, the first to come out of their $105 million partnership.
Pfizer creates COO role, Bayer replaces consumer health chief, Turnstone poaches Bristol-Myers executive as new R&D head and more.
The pact tasks CureVac with developing Cas9 mRNA constructs for use in three in vivo gene-editing liver disease programs.
Biogen poached a Pfizer medicinal sciences executive, AstraZeneca made two new oncology hires, Moderna tapped an industry veteran to oversee manufacturing.
Get Tuesday's prescription for biopharma news of note.